Full-Time

Executive Director

Intellectual Property

Confirmed live in the last 24 hours

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Biotechnology
Healthcare

Expert

Remote in USA

Remote work is available for candidates based in the US.

Category
Intellectual Property (IP)
Legal & Compliance

You match the following Sana Biotechnology's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelors plus at least 15 yrs or equivalent combination of relevant education and experience
  • Ph.D. degree
  • Membership in at least one state bar
  • Admitted to practice before the U.S. Patent and Trademark Office
  • 7+ years experience in patent drafting and prosecution, including global portfolios
  • Experience managing high-volume intellectual property workflow
  • Intense commitment to high moral standards and business ethics
  • Significant experience in evaluating complex patent landscapes, infringement and validity analyses, and risk evaluation and mitigation strategies
  • Ability to handle complex intellectual property matters with an ability to think strategically and granularly
  • Experience in in-licensing and other complex business transactions
  • Strong collaborator who can work successfully and build relationships with internal legal colleagues, internal stakeholders, and external parties to achieve business goals
  • Excellent oral and written communication skills, articulate, direct and forthright
  • Strong organizational and administrative skills
  • Must have attention to detail and excellent drafting skills
  • Strong ability to adapt to changes and be agile
Responsibilities
  • Become embedded with R&D to develop a deep understanding of the science and technologies at Sana
  • Lead and develop the IP strategy for certain pre-clinical and clinical programs, including building, drafting, and prosecuting patent portfolios
  • Partner with R&D to identify patentable subject matter and implement patent protection strategies
  • Work with the R&D team to advise and guide on intellectual property development and strategy
  • Conduct or direct patent landscape and third party patent searches and develop strategies for freedom-to-operate, infringement and validity analyses, risk evaluation and mitigation strategies, adverse proceedings, and litigation activities
  • Partner with other business functions to provide strategic advice in connection with strategic transactions, licensing agreements, and research collaborations
  • Develop IP policies and provide IP-related education to the company
  • Manage external relationships with outside counsel and licensors/licensees
  • Stay informed of any changes to law, industry, and the external business environment
Desired Qualifications
  • Ph.D. degree in biochemistry, biology, immunology, or another technical field relevant to the biotech industry
  • Experience in the support and launch of commercial product candidates
  • Experience managing intellectual property and developing IP strategies for cellular and/or gene therapies
  • Experience both in the law firm and in-house legal department settings

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases. Their approach focuses on addressing the root causes of diseases by repairing genes within cells or replacing damaged cells. This method allows for the creation of new types of medicines that can enhance patient outcomes. Sana's main clients include healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The company invests heavily in research and development to discover and create new treatments, which they monetize through licensing agreements, partnerships, and direct sales. Unlike many competitors, Sana's focus on cellular and genetic medicine positions them uniquely in the biotechnology sector. Their goal is to improve patient care by providing effective treatments for a wide range of diseases, from genetic disorders to chronic conditions.

Company Size

201-500

Company Stage

IPO

Total Funding

$798.6M

Headquarters

Seattle, Washington

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Sana raised $189.75 million through a PIPE offering, showing strong investor confidence.
  • The new Bothell facility expands Sana's capacity for creating engineered cell medicines.
  • Fast Track designation for SC291 expedites development for high unmet need diseases.

What critics are saying

  • Increased competition from companies like BlueRock Therapeutics in regenerative medicine.
  • Resignation of key R&D figure, Dr. Douglas Williams, may disrupt innovation pipeline.
  • Opening a new facility in Bothell could strain financial and management resources.

What makes Sana Biotechnology unique

  • Sana focuses on engineered cells to treat diseases at genetic and cellular levels.
  • The company has FDA Fast Track designation for SC291 in autoimmune diseases.
  • Sana's R&D investments lead to innovative cellular therapies for unmet medical needs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Employee Stock Purchase Plan

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

5%

2 year growth

6%
GeekWire
Feb 11th, 2025
Kestra Medical Technologies, maker of wearable cardiac devices, files for IPO

Monday's filling marks the end of a long dry stretch with no traditional IPOs for Seattle-area tech companies since Sana Biotechnology went public in 2021.

GeekWire
Feb 11th, 2025
Kestra Medical Technologies, Maker Of Wearable Cardiac Devices, Files For Ipo

Kestra Medical Technologies device for detecting and responding to cardiac events. (Kestra Photo)Kestra Medical Technologies, a Kirkland, Wash.-based company selling cardiac monitoring and therapeutic devices, filed for an initial public offering on Monday.The company’s revenue more than tripled from $7.6 million in fiscal year 2023 to $27.8 million in the last fiscal year, which ended in April. Net losses for the same periods were $84.2 million in 2023 and $94.1 million last year, according to a filing with the U.S. Securities and Exchange Commission.Monday’s filling marks the end of a long dry stretch with no traditional IPOs for Seattle-area tech companies since Sana Biotechnology went public in 2021. Companies have gone public since that time via a special purpose acquisition company (SPAC), the most recent being Longevity Biomedical in 2023. This follows a broader trend that saw a surge in U.S

GlobeNewswire
Jan 8th, 2025
Sana Biotechnology To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer

GlobeNewswire
Dec 2nd, 2024
Sana Biotechnology Announces Fast Track Designation For Sc291 In Relapsed/Refractory Systemic Lupus Erythematosus

Fast Track designation is designed to expedite clinical development and regulatory review timelinesEnrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025SEATTLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for SC291 in relapsed/refractory systemic lupus erythematosus (SLE), which includes extrarenal lupus and lupus nephritis. Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.SC291, a hypoimmune (HIP)-modified CD19-directed allogeneic CAR T therapy, is being evaluated in Sana’s GLEAM trial in patients with B-cell mediated autoimmune diseases including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Sana is enrolling patients in this study and expects to share initial data in 2025.“We are pleased to receive Fast Track designation from the FDA for SC291, which highlights the need for new treatment options for patients with relapsed/refractory SLE,” said Dhaval Patel, M.D., Ph.D., Chief Scientific Officer of Sana

Yahoo Finance
Aug 26th, 2024
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

Sana Biotechnology appoints accomplished drug developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.